Cellular localization of Visudyne® as a function of time after local injection in an in vivo model of squamous cell carcinoma: An investigation into tumor cell death

Veterinary Ophthalmology

Volumn 13, Issue 3, 2010, Pages 158-165

  Barnes, Laura D ^a   Giuliano, Elizabeth A ^a   Ota, Juri ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Light emitting diode; Photodynamic therapy; Squamous cell carcinoma; Transmission electron

Indexed keywords

PHOTOSENSITIZING AGENT; PORPHYRIN; VERTEPORFIN;

ANIMAL; ARTICLE; CELL DEATH; DRUG EFFECT; EXPERIMENTAL NEOPLASM; HUMAN; LOW LEVEL LASER THERAPY; METABOLISM; MOUSE; NUDE MOUSE; SQUAMOUS CELL CARCINOMA; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; BIOLOGICAL TRANSPORT; CARCINOMA, SQUAMOUS CELL; CELL DEATH; CELL LINE, TUMOR; HUMANS; LASER THERAPY; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PHOTOSENSITIZING AGENTS; PORPHYRINS;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 77953689875     PISSN: 14635216     EISSN: 14635224     Source Type: Journal    
DOI: 10.1111/j.1463-5224.2010.00775.x     Document Type: Article

References (58)

1. Calista D, Coccia L. Photodynamic therapy for the treatment of in situ squamous cell carcinoma of the left eyelid. International Journal of Dermatology 2008, 47:1319-1321.
2. Morton C, Horn M, Leman J. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Archives of Dermatology 2006, 142:729-735.
3. Puizina-Ivic N, Zorc H, Vanjaka-Rogosic L. Fractionated illumination improves the outcome in the treatment of precancerous lesions with photodynamic therapy. Collegium Antropologicum 2008, 32(Suppl. 2):67-73.
4. Rossi R, Assad GB, Buggiani G. Photodynamic therapy: treatment of choice for actinic cheilitis? Dermatologic Therapy 2008, 21:412-415.
5. Tierney E, Barker A, Ahdout J. Photodynamic therapy for the treatment of cutaneous neoplasia, inflammatory disorders, and photoaging. Dermatologic Surgery 2009, 35:725-746.
6. Wang XL, Wang HW, Guo MX. Treatment of skin cancer and pre-cancer using topical ALA-PDT - a single hospital experience. Photodiagnosis and Photodynamic Therapy 2008, 5:127-133.
7. Reeds KB, Ridgway TD, Higbee RG. Non-coherent light for photodynamic therapy of superficial tumours in animals. Veterinary and Comparative Oncology 2004, 2:157-163.
8. Osaki T, Takagi S, Hoshino Y. Efficacy of antivascular photodynamic therapy using benzoporphyrin derivative monoacid ring A (BPD-MA) in 14 dogs with oral and nasal tumors. Journal of Veterinary Medical Science 2009, 71:125-132.
9. Osaki T, Hoshino S, Hoshino Y. Clinical pharmacokinetics of anti-angiogenic photodynamic therapy with benzoporphyrin derivative monoacid ring-A in dogs having naturally occurring neoplasms. Journal of Veterinary Medicine Series A: Physiology Pathology Clinical Medicine 2006, 53:108-112.
10. McCaw DL, Pope ER, Payne JT. Treatment of canine oral squamous cell carcinomas with photodynamic therapy. British Journal of Cancer 2000, 82:1297-1299.
11. Hahn KA, Panjehpour M, Legendre AM. Photodynamic therapy response in cats with cutaneous squamous cell carcinoma as a function of fluence. Veterinary Dermatology 1998, 9:3-7.
12. Bexfield NH, Stell AJ, Gear RN. Photodynamic therapy of superficial nasal planum squamous cell carcinomas in cats: 55 cases. Journal of Veterinary Internal Medicine 2008, 22:1385-1389.
13. Giuliano EA, MacDonald I, McCaw DL. Photodynamic therapy for the treatment of periocular squamous cell carcinoma in horses: a pilot study. Veterinary Ophthalmology 2008, 11(Suppl. 1):27-34.
14. Dougherty TJ, Gomer CJ, Henderson BW. Photodynamic therapy. Journal of the National Cancer Institute 1998, 90:889-905.
15. MacDonald IJ, Dougherty TJ. Basic principles of photodynamic therapy. Journal of Porphyrins and Phthalocyanines 2001, 5:105-129.
16. Giuliano EA, Ota J, Tucker SA. Photodynamic therapy: basic principles and potential uses for the veterinary ophthalmologist. Veterinary Ophthalmology 2007, 10:337-343.
17. Cairns RA, Khokha R, Hill RP. Molecular mechanisms of tumor invasion and metastasis: an integrated view. Current Molecular Medicine 2003, 3:659-671.
18. Zhou X, Pogue BW, Chen B. Pretreatment photosensitizer dosimetry reduces variation in tumor response. International Journal of Radiation Oncology Biology Physics 2006, 64:1211-1220.
19. Andrejevic Blant S, Ballini JP, Van Den Bergh H. Time-dependent biodistribution of tetra(m-hydroxyphenyl)chlorin and benzoporphyrin derivative monoacid ring A in the hamster model: comparative fluorescence microscopy study. Photochemistry and Photobiology 2000, 71:333-340.
20. Ji Z, Yang G, Vasovic V. Subcellular localization pattern of protoporphyrin IX is an important determinant for its photodynamic efficiency of human carcinoma and normal cell lines. Journal of Photochemistry and Photobiology B, Biology 2006, 84:213-220.
21. Aggio FB, Melo GB, Hofling-Lima AL. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration. Acta Ophthalmologica Scandinavica 2006, 84:831-833.
22. Dhalla MS, Shah GK, Blinder KJ. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006, 26:988-993.
23. Kaiser PK, Boyer DS, Garcia R. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2009, 116:747-755.
24. Lu F, Hu Z, Sinard J. Factor VII-verteporfin for targeted photodynamic therapy in a rat model of choroidal neovascularization. Investigative Ophthalmology and Visual Science 2009, 59:3890-3896.
25. Maier M, Haas K, Feucht N. [Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for occult and classic CNV in AMD]. Klinische Monatsblätter für Augenheilkunde 2008, 225:653-659.
26. Shah GK, Sang DN, Hughes MS. Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration. Retina 2009, 29:133-148.
27. Smith BT, Dhalla MS, Shah GK. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina 2008, 28:675-681.
28. Chen B, Pogue BW, Hoopes PJ. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. International Journal of Radiation Oncology, Biology, Physics 2005, 61:1216-1226.
29. Bressler NM, Arnold J, Benchaboune M. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Archives of Ophthalmology 2002, 120:1443-1454.
30. Keam SJ, Scott LJ, Curran MP. Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation. Drugs 2003, 63:2521-2554.
31. Pogue BW, O'Hara JA, Demidenko E. Photodynamic therapy with verteporfin in the radiation-induced fibrosarcoma-1 tumor causes enhanced radiation sensitivity. Cancer Research 2003, 63:1025-1033.
32. Lavach JD, Severin GA. Neoplasia of the equine eye, adnexa, and orbit: a review of 68 cases. Journal of the American Veterinary Medical Association 1977, 170:202-203.
33. Gelatt KN, Myers VS, Perman V. Conjunctival squamous cell carcinoma in the horse. Journal of the American Veterinary Medical Association 1974, 165:617-620.
34. Koch SA, Cowles RR. Surgical removal of squamous cell carcinoma of the equine eye. Veterinary Medicine, Small Animal Clinician: VM, SAC 1971, 66:327-329.
35. Hilbert BJ, Farrell RK, Grant BD. Cryotherapy of periocular squamous cell carcinoma in the horse. Journal of the American Veterinary Medical Association 1977, 170:1305-1308.
36. Grier RL, Brewer WG. Treatment of bovine and equine ocular squamous cell carcinoma by radiofrequency hyperthermia. Journal of the American Veterinary Medical Association 1980, 177:55-61.
37. Frauenfelder HC, Blevins WE, Page EH. 90Sr for treatment of periocular squamous cell carcinoma in the horse. Journal of the American Veterinary Medical Association 1982, 180:307-309.
38. Theon AP, Pascoe JR, Carlson GP. Intratumoral chemotherapy with cisplatin in oily emulsion in horses. Journal of the American Veterinary Medical Association 1993, 202:261-267.
39. Hendrix DVH. Equine ocular squamous cell carcinoma. Clinical Techniques in Equine Practice 2005, 4:87-94.
40. Ota J, Giuliano EA, Cohn LA. Local photodynamic therapy for equine squamous cell carcinoma: evaluation of a novel treatment method in a murine model. The Veterinary Journal 2008, 176:170-176.
41. Barnes LD, Giuliano EA, Ota J. The effect of photodynamic therapy on squamous cell carcinoma in a murine model: evaluation of time between intralesional injection to laser irradiation. The Veterinary Journal 2009, 180:60-65.
42. McLellan MR, Day JG. Cryopreservation and freeze-drying protocols. Introduction. Methods in Molecular Biology 1995, 38:1-5.
43. Goldman L. Chromophores in tissue for laser medicine and laser surgery. Lasers in Medical Science 1990, 5:289-292.
44. Tanaka N, Sugihara K, Odajima T. Oral squamous cell carcinoma: electron microscopic and immunohistochemical characteristics. Medical Electron Microscopy 2002, 35:127-138.
45. Picard O, Rolland Y, Poupon MF. Fibroblast-dependent tumorigenicity of cells in nude mice: implication for implantation of metastases. Cancer Research 1986, 46:3290-3294.
46. Mitra S, Foster TH. In vivo confocal fluorescence imaging of the intratumor distribution of the photosensitizer mono-L-aspartylchlorin-e6. Neoplasia 2008, 10:429-438.
47. Spigulis J, Lihachev A, Erts R. Imaging of laser-excited tissue autofluorescence bleaching rates. Applied Optics 2009, 48:D163-D168.
48. Tadrous PJ, Siegel J, French PM. Fluorescence lifetime imaging of unstained tissues: early results in human breast cancer. The Journal of Pathology 2003, 199:309-317.
49. Wyld L, Reed MW, Brown NJ. Differential cell death response to photodynamic therapy is dependent on dose and cell type. The British Journal of Cancer 2001, 84:1384-1386.
50. Osaki T, Takagi S, Hoshino Y. Intracellular localization and concentration as well as photodynamic effects of benzoporphyrin derivative monoacid ring A in four types of rodent tumor cells. Cancer Letters 2006, 243:281-292.
51. Kessel D, Luo Y. Mitochondrial photodamage and PDT-induced apoptosis. Journal of Photochemistry and Photobiology B, Biology 1998, 42:89-95.
52. Liu X, Kim CN, Yang J. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996, 86:147-157.
53. Hacker G. The morphology of apoptosis. Cell and Tissue Research 2000, 301:5-17.
54. Bartosik J, Stender IM, Kobayasi T. Ultrastructural alteration of tape-stripped normal human skin after photodynamic therapy. European Journal of Dermatology 2004, 14:91-95.
55. Korbelik M, Merchant S, Huang N. Exploitation of immune response-eliciting properties of hypocrellin photosensitizer SL052-based photodynamic therapy for eradication of malignant tumors. Photochemistry and Photobiology 2009, 85:1418-1424.
56. Korbelik M, Cecic I. Enhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment. Journal of Photochemistry and Photobiology B: Biology 1998, 44:151-158.
57. Fantini F, Greco A, Cesinaro AM. Pathologic changes after photodynamic therapy for Basal cell carcinoma and Bowen disease: a histologic and immunohistochemical investigation. Archives of Dermatology 2008, 144:186-194.
58. Krosl G, Korbelik M, Dougherty GJ. Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. British Journal of Cancer 1995, 71:549-555.